Abstract:Anaplastic lymphoma kinase (ALK)-positive (ALK(+)) patients exhibit unique clinical characteristics. It would be beneficial to effectively predict their treatment outcome. We assessed the performance of the radiomic signature from nonesmall-cell lung cancer for predicting ALK(+) patient outcomes using the least absolute shrinkage and selection operator Cox regression model. Its performance was impaired when used for ALK(+) patients treated with tyrosine kinase inhibitors (TKIs). Therefore, developing special signatures for patients treated with TKIs might be needed. Background: The purpose of the study was to investigate the potential of a radiomic signature developed in a general nonesmall-cell lung cancer (NSCLC) cohort for predicting the overall survival of anaplastic lymphoma kinase (ALK)positive (ALK(+)) patients with different treatment types. Materials and Methods: After test-retest in the Reference Image Database to Evaluate Therapy Response data set, 132 features (intraclass correlation coefficient > 0.9) were selected in the least absolute shrinkage and selection operator Cox regression model with a leave-one-out cross-validation. The NSCLC radiomics collection from The Cancer Imaging Archive was randomly divided into a training set (n = 254) and a validation set (n = 63) to develop a general radiomic signature for NSCLC. In our ALK(+) set, 35 patients received targeted therapy and 19 patients received nontargeted therapy. The developed signature was tested later in this ALK(+) set. Performance of the signature was evaluated with the concordance index (C-index) and stratification analysis. Results: The general signature had good performance (C-index > 0.6; log rank P <.05) in the NSCLC radiomics collection. It includes 5 features: Geom_va_ratio, W_GLCM_Std, W_GLCM_DV, W_GLCM_IM2, and W_his_mean. Its accuracy of predicting overall survival in the ALK(+) set achieved 0.649 (95% confidence interval [CI], 0.640-0.658). Nonetheless, impaired performance was observed in the targeted therapy group (C-index = 0.573; 95% CI, 0.556-0.589) whereas significantly improved performance was observed in the nontargeted therapy group (C-index = 0.832; 95% CI, 0.832-0.852). Stratification analysis also showed that the general signature could only identify high- and low-risk patients in the nontargeted therapy group (log rank P = .00028). Conclusion: This preliminary study suggests that the applicability of a general signature to ALK(+) patients is limited. The general radiomic signature seems to be only applicable to ALK(+) patients who had received nontargeted therapy, which indicates that developing special radiomics signatures for patients treated with tyrosine kinase inhibitors might be necessary.

MRI Radiomic Signature Predicts Intracranial Progression-Free Survival in Patients with Brain Metastases of ALK-positive Non-Small Cell Lung Cancer

Delta Radiomics Model for the Prediction of Progression-Free Survival Time in Advanced Non-Small-cell Lung Cancer Patients after Immunotherapy.

Radiomic-signature Changes after Early Treatment Improve the Prediction of Progression-Free Survival in Patients with Advanced Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer.

Application of Radiomics Signature Captured from Pretreatment CT to Predict Brain Metastases in Stage III/IV Non-small Cell Lung Cancer Patients with ALK Mutation

A CT‐based Radiomics Model to Predict Subsequent Brain Metastasis in Patients with ALK‐rearranged Non–small Cell Lung Cancer Undergoing Crizotinib Treatment

Predicting Survival Duration With MRI Radiomics of Brain Metastases From Non-small Cell Lung Cancer

MRI radiomics for predicting intracranial progression in non-small-cell lung cancer patients with brain metastases treated with epidermal growth factor receptor tyrosine kinase inhibitors

Pretreatment Thoracic CT Radiomic Features to Predict Brain Metastases in Patients With ALK-Rearranged Non-Small Cell Lung Cancer

Radiomics of metastatic brain tumor as a predictive image biomarker of progression-free survival in patients with non-small-cell lung cancer with brain metastasis receiving tyrosine kinase inhibitors

Application of Radiomics Signature Captured from Pretreatment Thoracic CT to Predict Brain Metastases in Stage III/IV ALK-positive Non-Small Cell Lung Cancer Patients

CT-Based Radiomic Signature As a Prognostic Factor in Stage IV ALK-Positive Non-small-cell Lung Cancer Treated with TKI Crizotinib: A Proof-of-Concept Study

MRI Radiomics Predicts the Efficacy of EGFR-TKI in EGFR-Mutant Non-Small-Cell Lung Cancer with Brain Metastasis

Comparison of clinical and MRI features of brain metastases between ALK+ and ALK‐ NSCLC

Assessment of a Radiomic Signature Developed in a General NSCLC Cohort for Predicting Overall Survival of ALK-Positive Patients with Different Treatment Types.

Multiregional radiomics of brain metastasis can predict response to EGFR-TKI in metastatic NSCLC

Development and validation of a magnetic resonance imaging radiomics-based signature to predict axillary lymph node metastasis and disease-free survival in patients with breast cancer: A multicenter cohort study

7P Machine Learning Intratumoral and Axillary Lymph Node Magnetic Resonance Imaging Radiomics for Predicting Axillary Lymph Node Metastasis in Patients with Early-Stage Invasive Breast Cancer (RBC-01 Study)

Using MRI radiomics to predict the efficacy of immunotherapy for brain metastasis in patients with small cell lung cancer

Differentiating EGFR from ALK mutation status using radiomics signature based on MR sequences of brain metastasis

Computed tomography-based radiomics and clinical-genetic features for brain metastasis prediction in patients with stage III/IV epidermal growth factor receptor-mutant non-small-cell lung cancer

Enhancing intracranial efficacy prediction of osimertinib in non-small cell lung cancer: a novel approach through brain MRI radiomics